CA2417874A1 - Utilisation des inhibiteurs ox-2 pour le traitement du cancer - Google Patents

Utilisation des inhibiteurs ox-2 pour le traitement du cancer Download PDF

Info

Publication number
CA2417874A1
CA2417874A1 CA002417874A CA2417874A CA2417874A1 CA 2417874 A1 CA2417874 A1 CA 2417874A1 CA 002417874 A CA002417874 A CA 002417874A CA 2417874 A CA2417874 A CA 2417874A CA 2417874 A1 CA2417874 A1 CA 2417874A1
Authority
CA
Canada
Prior art keywords
agent
protein
molecule
effective amount
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002417874A
Other languages
English (en)
Other versions
CA2417874C (fr
Inventor
Reginald M. Gorczynski
David A. Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trillium Therapeutics ULC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2417874A1 publication Critical patent/CA2417874A1/fr
Application granted granted Critical
Publication of CA2417874C publication Critical patent/CA2417874C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés et des compositions permettant de réguler la croissance des tumeurs. Afin de réduire la croissance tumorale, on administre des agents qui inhibent OX-2. Ces procédés sont utiles dans le traitement du cancer. Afin d'accroître la croissance tumorale, on administre une protéine OX-2 ou un acide nucléique codant une protéine OX-2. Ces procédés sont utiles dans la recherche sur le cancer et/ou la métastase tumorale.
CA2417874A 2000-08-03 2001-07-30 Utilisation des inhibiteurs ox-2 pour le traitement du cancer Expired - Fee Related CA2417874C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22272500P 2000-08-03 2000-08-03
US60/222,725 2000-08-03
PCT/CA2001/001111 WO2002011762A2 (fr) 2000-08-03 2001-07-30 Procedes et compositions utiles pour moduler la croissance des tumeurs

Publications (2)

Publication Number Publication Date
CA2417874A1 true CA2417874A1 (fr) 2002-02-14
CA2417874C CA2417874C (fr) 2012-10-02

Family

ID=22833418

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2417874A Expired - Fee Related CA2417874C (fr) 2000-08-03 2001-07-30 Utilisation des inhibiteurs ox-2 pour le traitement du cancer

Country Status (3)

Country Link
AU (1) AU2001278338A1 (fr)
CA (1) CA2417874C (fr)
WO (1) WO2002011762A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2429579A1 (fr) * 2000-11-22 2002-05-30 Trillium Therapeutics Inc. Cd200 tronquee
US7427665B2 (en) 2000-12-08 2008-09-23 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line
AU2004217434B2 (en) * 2000-12-08 2010-08-26 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
MXPA05006978A (es) * 2002-12-27 2005-08-16 Schering Corp Metodos para inducir y mantener la tolerancia inmune.
AU2012211347B9 (en) * 2004-07-20 2015-06-18 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
HUE028179T2 (en) 2006-01-12 2016-12-28 Alexion Pharma Inc Antibodies to OX-2 / CD200 and their use
WO2009014744A1 (fr) 2007-07-25 2009-01-29 Alexion Pharmaceutical, Inc. Procédés et compositions pour traiter une maladie auto-immune
CA2786692A1 (fr) 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarqueurs d'effets immunomodulateurs chez des humains traites par des anticorps anti-cd200
WO2011100538A1 (fr) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Procédés thérapeutiques utilisant des anticorps anti-cd200
EP2723380B1 (fr) 2011-06-24 2019-08-21 Stephen D. Gillies Protéines hybrides d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
WO2019126133A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Formulations liquides d'anticorps anti-cd200

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1032662B1 (fr) * 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Procedes et compositions pour immunomodulation

Also Published As

Publication number Publication date
AU2001278338A1 (en) 2002-02-18
WO2002011762A2 (fr) 2002-02-14
CA2417874C (fr) 2012-10-02
WO2002011762A3 (fr) 2003-03-13

Similar Documents

Publication Publication Date Title
CA2417874A1 (fr) Utilisation des inhibiteurs ox-2 pour le traitement du cancer
ATE334657T1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
GEP20053424B (en) Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
WO2004076644A3 (fr) Composition pour la delivrance d'un agent a une cellule cible et ses utilisations
Feldman et al. Binding of α2-macroglobulin to hepatocytes: mechanism of in vivo clearance
GB2370774A (en) Anti-infective compositions for treating disordered tissue such as cold sores
WO2003070283A3 (fr) Agent inhibant l'evolution ou la progression des maladies proliferatives, en particulier des cancers, et composition pharmaceutique contenant ledit agent
BR0110927A (pt) Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
AU7621600A (en) Human rnase h and oligonucleotide compositions thereof
BR0109517A (pt) métodos e composições sinérgicas para tratar o cáncer
DE60227492D1 (de) Hemmstoffe der akt aktivität
WO2002009684A3 (fr) Inhibiteur de l'erbb-2 kinase selectif de petites molecules
IL162836A (en) Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments and pharmaceutical compositions thereof
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
EA200500300A1 (ru) Цитотоксические агенты, содержащие новые сильнодействующие таксаны, и их терапевтическое применение
DE69907419D1 (en) Antitumorwirkstoffe
Dalbies et al. Linkage isomerization reaction of intrastrand cross-links in trans-diamminedichloroplatinum (II)-modified single-stranded oligonucleotides
WO2003017939A3 (fr) Composes de piperazinone utilises comme agents antitumoraux et anticancereux et procedes de traitement
WO2004009112A8 (fr) Utilisation d'urease pour inhiber la croissance de cellules cancereuses
AU3881095A (en) Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
WO2023092153A3 (fr) Méthodes et compositions ciblant la protéine-1 associée au noyau accumbens pour le traitement de troubles auto-immuns et de cancers
BRPI0414812A (pt) método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres
MXPA02010813A (es) Fosforamidatos de bis-(n,n'-bis-(2-haloetil)amino) como agentes antitumor.
AU2001220255A1 (en) Human cervical cancer suppressor protein, polynucleotide encoding the protein, cell transformed with the polynucleotide and method for suppressing proliferationof cancer cell using the expression vector
Zylicz et al. In vitro modulation of cisplatin cytotoxicity by sparsomycin inhibition of protein synthesis

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140730